Timothy Breen
Overview
Explore the profile of Timothy Breen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
6
Citations
148
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bogan Jr J, OHanlon B, Steen D, Horan T, Taylor R, Mason A, et al.
J Wildl Dis
. 2023 Nov;
60(1):39-51.
PMID: 37972635
There is a paucity of information regarding the health status of free-ranging eastern indigo snakes (EIS; Drymarchon couperi) in heavily modified and developing landscapes. As a component of regional Florida...
2.
Hahn N, Bivalacqua T, Ross A, Netto G, Baras A, Park J, et al.
Clin Cancer Res
. 2016 Dec;
23(12):3003-3011.
PMID: 27932416
To assess the clinical and pharmacodynamic activity of dovitinib in a treatment-resistant, molecularly enriched non-muscle-invasive urothelial carcinoma of the bladder (NMIUC) population. A multi-site pilot phase II trial was conducted....
3.
Adra N, Albany C, Brames M, Case-Eads S, Johnson C, Liu Z, et al.
Support Care Cancer
. 2016 Feb;
24(7):2837-42.
PMID: 26838019
Purpose: A phase III study adding aprepitant to a 5HT3 receptor antagonist (5HT3-RA) plus dexamethasone in germ cell tumor (GCT) patients treated with 5-day cisplatin combination chemotherapy demonstrated a significant...
4.
Hahn N, Knudsen B, Daneshmand S, Koch M, Bihrle R, Foster R, et al.
Urol Oncol
. 2015 Sep;
34(1):4.e11-7.
PMID: 26362343
Objectives: Preclinical urothelial carcinoma models suggest activity of dasatinib, an oral SRC-family kinase (SFK) inhibitor. We sought to determine the feasibility and biologic activity of neoadjuvant dasatinib (Neo-D) in patients...
5.
Pal S, Azad A, Bhatia S, Drabkin H, Costello B, Sarantopoulos J, et al.
Clin Cancer Res
. 2015 Mar;
21(15):3420-7.
PMID: 25788492
Purpose: BNC105P inhibits tubulin polymerization, and preclinical studies suggest possible synergy with everolimus. In this phase I/II study, efficacy and safety of the combination were explored in patients with metastatic...
6.
Fang F, Balch C, Schilder J, Breen T, Zhang S, Shen C, et al.
Cancer
. 2010 Jun;
116(17):4043-53.
PMID: 20564122
Background: Aberrant DNA methylation is a hallmark of cancer, and DNA methyltransferase inhibitors have demonstrated clinical efficacy in hematologic malignancies. On the basis of preclinical studies indicating that hypomethylating agents...